Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 4/20 | 0.77 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.77 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.77 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.77 |
| ▸ | KDR | P35968 | 2/20 | 0.50 |
| ▸ | FLT1 | P17948 | 1/20 | 0.50 |
| ▸ | FLT4 | P35916 | 1/20 | 0.50 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.50 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.50 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.50 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2126398 | 0.91 | TGFBR1 (0.64) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL24744356 | 0.88 | TGFBR1 (0.77) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL14344430 | 0.88 | TGFBR1 (0.80) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL29381400 | 0.87 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL411646 | 0.87 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL29361383 | 0.87 | TGFBR1 (1.00) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL2128905 | 0.87 | TGFBR1 (0.59) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL14344351 | 0.84 | TGFBR1 (0.74) | TGFBR1PRKD3PRKD1PRKD2KDR | |
| SCHEMBL14344388 | 0.84 | PRKD3 (0.55) | TGFBR1PRKD3PRKD1PRKD2ABCG2 | |
| SCHEMBL14344357 | 0.83 | TGFBR1 (0.72) | TGFBR1PRKD3PRKD1PRKD2MAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-9951075-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2018-04-24 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | JANSSEN SCIENCES IRELAND UC (IE) | 2017-09-28 | — | — | US | disclosed |
| US-9708328-B2 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | JANSSEN SCIENCES IRELAND UC (IE) | 2017-07-18 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciences Ireland Unlimited Company (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | Janssen Sciencies Ireland UC (IE) | 2016-06-09 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2009-06-18 | — | — | US | disclosed |
| CN-101171014-A | Pteridines useful as HCV inhibitors and methods for the preparation thereof | TIBOTEC PHARM LTD (IE) | 2008-04-30 | — | — | CN | disclosed |
| EP-1881834-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | Tibotec Pharmaceuticals Ltd. (IE) | 2008-01-30 | — | — | EP | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SCIOS, INC. | 2007-12-20 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| US-7232824-B2 | Quinazoline derivatives as medicaments | SCIOS, INC. (US) | 2007-06-19 | — | — | US | disclosed |
| WO-2006120251-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160159803-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20170275288-A1 | PTERIDINES USEFUL AS HCV INHIBITORS AND METHODS FOR THE PREPARATION THEREOF | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20070293500-A1 | QUINAZOLINE DERIVATIVES AS MEDICAMENTS | SMAD3, SMAD2, TGFB2 | TGFBR1 8/4885PRKD3 1661/4885PRKD1 2216/4885 |
| US-20160158238-A1 | Pteridines Useful As HCV Inhibitors And Methods For The Preparation Thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
| US-20090156595-A1 | Pteridines useful as HCV inhibitors and methods for the preparation thereof | HCCS, HAVCR2, MAVS | TGFBR1 4569/4885PRKD3 2630/4885PRKD1 2798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.